AU1975099A - Reagents specific for st2l and uses therefor - Google Patents

Reagents specific for st2l and uses therefor

Info

Publication number
AU1975099A
AU1975099A AU19750/99A AU1975099A AU1975099A AU 1975099 A AU1975099 A AU 1975099A AU 19750/99 A AU19750/99 A AU 19750/99A AU 1975099 A AU1975099 A AU 1975099A AU 1975099 A AU1975099 A AU 1975099A
Authority
AU
Australia
Prior art keywords
st2l
uses therefor
reagents specific
reagents
specific
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU19750/99A
Inventor
Foo Yew Liew
Damo Xu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Glasgow
Original Assignee
University of Glasgow
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Glasgow filed Critical University of Glasgow
Publication of AU1975099A publication Critical patent/AU1975099A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
AU19750/99A 1997-12-24 1998-12-24 Reagents specific for st2l and uses therefor Abandoned AU1975099A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9727172 1997-12-24
GBGB9727172.0A GB9727172D0 (en) 1997-12-24 1997-12-24 Reagents specific for st2l and uses therefor
PCT/GB1998/003913 WO1999034217A1 (en) 1997-12-24 1998-12-24 Reagents specific for st2l and uses therefor

Publications (1)

Publication Number Publication Date
AU1975099A true AU1975099A (en) 1999-07-19

Family

ID=10824117

Family Applications (1)

Application Number Title Priority Date Filing Date
AU19750/99A Abandoned AU1975099A (en) 1997-12-24 1998-12-24 Reagents specific for st2l and uses therefor

Country Status (3)

Country Link
AU (1) AU1975099A (en)
GB (1) GB9727172D0 (en)
WO (1) WO1999034217A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6323334B1 (en) 1999-09-24 2001-11-27 Millennium Pharmaceuticals, Inc. Nucleic acid molecules encoding a 103 gene product and uses therefor
WO2002038794A2 (en) 2000-11-09 2002-05-16 The Brigham And Women's Hospital, Inc. Cardiovascular disease diagnostic and therapeutic targets
US7670769B2 (en) 2002-05-09 2010-03-02 The Brigham And Women's Hospital, Inc. IL1RL-1 as a cardiovascular disease marker and therapeutic target
NZ549040A (en) 2004-02-17 2009-07-31 Schering Corp Use for interleukin-33 (IL33) and the IL-33 receptor complex
JP5383480B2 (en) 2006-04-24 2014-01-08 クリティカル ケア ダイアグノスティクス インコーポレイテッド Predict fatality and detect serious disease
EP3059594A1 (en) 2006-05-01 2016-08-24 Critical Care Diagnostics, Inc. Prognosis of cardiovascular disease
US8147817B2 (en) 2006-05-04 2012-04-03 The Brigham And Women's Hospital, Inc. IL-33 in the treatment and diagnosis of diseases and disorders
PT2660599E (en) 2008-04-18 2014-11-28 Critical Care Diagnostics Inc Predicting risk of major adverse cardiac events
WO2011127412A2 (en) 2010-04-09 2011-10-13 Critical Care Diagnostics, Inc. Soluble human st-2 antibodies and assays
AU2016269576B2 (en) * 2010-04-09 2018-11-08 Critical Care Diagnostics, Inc. Soluble human ST-2 antibodies and assays
AU2013204182B2 (en) * 2010-04-09 2016-09-15 Critical Care Diagnostics, Inc. Soluble human ST-2 antibodies and assays
TW201238976A (en) * 2011-02-23 2012-10-01 Hoffmann La Roche Antibodies against human IL33R and uses thereof
US9212227B2 (en) 2012-04-30 2015-12-15 Janssen Biotech, Inc. ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions
JO3623B1 (en) 2012-05-18 2020-08-27 Amgen Inc St2 antigen binding proteins
WO2015164354A1 (en) 2014-04-21 2015-10-29 The Childen's Hospital Of Philadelphia Compositions and methods for treating cytokine-related disorders
CN112457392B (en) * 2021-01-27 2021-04-27 天津奇云诺德生物医学有限公司 Soluble ST2 protein antigenic determinant polypeptide and application thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5576191A (en) * 1994-06-17 1996-11-19 Immunex Corporation Cytokine that binds ST2

Also Published As

Publication number Publication date
GB9727172D0 (en) 1998-02-25
WO1999034217A1 (en) 1999-07-08

Similar Documents

Publication Publication Date Title
AU8121098A (en) Cell activation process and reagents therefor
AU9599498A (en) Biosensor
AU8766098A (en) Assay methods and apparatus
AU9586798A (en) Analyte assaying device
AU6055798A (en) Multi-well plate
AUPO797897A0 (en) Media device (ART18)
AU1709299A (en) Mixer-injectors
AUPP103497A0 (en) Assay apparatus
AU1027499A (en) 32P-polyphosphazene
AU3702397A (en) Anti-herpesviral agents and assays therefor
AU8173098A (en) Neuroprotective methods and reagents
AU1975099A (en) Reagents specific for st2l and uses therefor
AU8388798A (en) Biochemical reactor
AU4963797A (en) Rapid microbiological assay
AU5272198A (en) EMP-charge-eliminator
AU9159198A (en) Workbench
AU8358398A (en) Immunoassay apparatus
AU1527499A (en) Pen
AU4117497A (en) Micropolarimeter
AU8682998A (en) Improvement in chemical analyses
AU3166897A (en) Factor vii-binding reagent
AU6613998A (en) Sample transfer
AU3394995A (en) Bioluminescence and assay reagents
AU8227898A (en) Biological data
AU5531796A (en) Reagent specific for apolipoprotein-j polymorphisms and uses thereof

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase